COMMUNIQUÉS West-GlobeNewswire

Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne
21/12/2018
REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing [...]
Nabriva Therapeutics Announces Closing of up to a $75 million Term Loan
21/12/2018
-Financing Strengthens Cash Position Ahead of Two Potential Product Launches in 2019- DUBLIN, Ireland, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company [...]
Recro Pharma Amends IV Meloxicam License Agreement with Alkermes
21/12/2018
Reduces 2019 Cash Requirements by $30 Million; Extends Approval Milestone Payments Over Seven Years MALVERN, Pa., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty [...]
Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305
21/12/2018
STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with [...]
Holding(s) in Company
21/12/2018
Holding(s) in Company December 21, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Shire Plc JE00B2QKY057 1b. [...]
ViroGates financial calendar 2019
21/12/2018
Company announcement no. 9-2018 Birkerød, 21 December 2018 ViroGates A/S (Nasdaq First North Denmark: VIRO) has published its financial calendar for 2019 with the following key dates: 20 March Deadline for submission of [...]
HEXO Corp, licensed cannabis company, delivers on commitment to seek a listing on the NYSE
21/12/2018
Application made to list shares on the NYSE American GATINEAU, Quebec, Dec. 21, 2018 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO ), a leading licensed cannabis company based in Canada, is pleased [...]
HEXO Corp, producteur autorisé de cannabis, respecte son engagement à inscrire ses actions au NYSE
21/12/2018
Dépôt d’une demande d’inscription d’actions à la cote du NYSE American GATINEAU, Québec, 21 déc. 2018 (GLOBE NEWSWIRE) -- HEXO Corp (« HEXO » ou la « Société ») (TSX: HEXO ), un important producteur autorisé canadien de [...]
Genetic Technologies Limited Provides End of Year Update on the Test Development Program
21/12/2018
MELBOURNE, Australia, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic [...]
Nexstim Plc's Financial Information in 2019
21/12/2018
Company announcement, Helsinki, 21 December 2018 at 09.00 Nexstim Plc's Financial Information in 2019 Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering [...]
Herantis Pharma Oyj: Manager's Transactions - Pekka Simula
21/12/2018
Herantis Pharma Oyj: Manager's Transactions - Pekka Simula Herantis Pharma Plc Company release 21 December 2018 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person [...]
Nicox recentre ses activités de recherche sur de nouveaux composés donneurs de NO inhibiteurs de la PDE-5 pour le glaucome et signature avec Novaliq d'un accord de collaboration
21/12/2018
Communiqué de presse Nicox recentre ses activités de recherche sur de nouveaux composés donneurs de NO inhibiteurs de la PDE-5 pour le glaucome et signe avec Novaliq un accord de collaboration sur des formulations [...]
Nicox Focuses Research Activities on Novel NO-Donating PDE5 Inhibitors for Glaucoma and Enters into Collaboration with Novaliq
21/12/2018
Press Release Nicox Focuses Research Activities on Novel NO-Donating PDE5 Inhibitors for Glaucoma and Enters into Collaboration with Novaliq on Innovative Topical Ophthalmic Formulations [...]
Sensorion Announces Publication of SENS-401 Data in Otology & Neurology Journal
21/12/2018
Improvement of hearing recovery above threshold for clinical relevance when SENS-401 was administered daily for 28 days delayed as much as 96 hrs after acoustic trauma in a preclinical model MONTPELLIER, France, Dec. 21 [...]
Biocartis Group NV: Disclosure of outstanding voting securities
21/12/2018
PRESS RELEASE : REGULATED INFORMATION 21 December 2018, 07:00 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 21 December 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative [...]
CROSSJECT : SUCCES DE L'AUGMENTATION DE CAPITAL D'UN MONTANT DE 4 MILLIONS D'EUROS
21/12/2018
Communiqué de Presse SUCCES DE L'AUGMENTATION DE CAPITAL D'UN MONTANT DE 4 MILLIONS D'EUROS Opération intégralement souscrite Règlement livraison des actions nouvelles le 28 décembre 2018 Dijon, le 21 décembre 2018 [...]
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
21/12/2018
Geneva, Switzerland and Boston, MA – December 21, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical- stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
IBA to install a proton therapy solution in Charleroi, Belgium, and Dosimetry update
21/12/2018
IBA receives purchase order to install its Proteus ® ONE compact proton therapy solution in Charleroi Strategic review of Dosimetry division ongoing Louvain-La-Neuve, Belgium, 21 December 2018 - IBA (Ion Beam [...]
IBA installera une solution de protonthérapie à Charleroi, Belgique, et informe sur son activité Dosimétrie
21/12/2018
IBA a reçu le bon de commande pour installer sa solution compacte de protonthérapie Proteus ® ONE à Charleroi La revue stratégique de la division Dosimétrie est toujours en cours Louvain-la-Neuve, Belgique, 21 décembre [...]

Pages